Alnylam Pharmaceuticals, Inc.
DE ˙ XTRA ˙ US02043Q1076
260,50 € ↑8,70 (3,46%)
2026-06-04
DEL PRIS
SecurityDE:DUL / Alnylam Pharmaceuticals, Inc.
InstitutionProfund Advisors Llc
Latest Disclosed Ownership14,647 shares
Latest Disclosed Value $ 4,846,253
Profund Advisors Llc reports 6.04% decrease in ownership of DUL / Alnylam Pharmaceuticals, Inc.

On April 24, 2026 - Profund Advisors Llc filed a 13F-HR form disclosing ownership of 14,647 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL) valued at $4,184,648 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 6, 2026 disclosing 15,589 shares of Alnylam Pharmaceuticals, Inc.. This represents a change in shares of -6.04% during the quarter. The current value of the position is $3,815,544 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-24 2026-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 14,647 -942 -6.04 4,846 -21.81 0.1779
2026-02-06 2025-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 15,589 12,053 340.87 6,199 284.49 0.1884
2025-11-06 2025-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,536 -2,882 -44.90 1,612 -22.94 0.0524
2025-08-07 2025-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 6,418 -2,408 -27.28 2,093 -12.21 0.0753
2025-05-08 2025-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 8,826 -869 -8.96 2,383 4.47 0.1036
2025-02-14 2024-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 9,695 -2,379 -19.70 2,281 -31.30 0.0833
2024-11-14 2024-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 12,074 -2,328 -16.16 3,321 -5.12 0.1256
2024-08-13 2024-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 14,402 5,132 55.36 3,500 152.64 0.1298
2024-05-08 2024-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 9,270 938 11.26 1,385 -13.11 0.0539
2024-02-14 2023-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 8,332 1,075 14.81 1,595 24.05 0.0685
2023-11-13 2023-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 7,257 -472 -6.11 1,285 -12.47 0.0711
2023-08-10 2023-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 7,729 959 14.17 1,468 8.26 0.0788
2023-05-12 2023-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 6,770 -6,954 -50.67 1,356 -58.42 0.0838
2023-02-02 2022-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 13,724 636 4.86 3,262 24.47 0.2116
2022-11-07 2022-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 13,088 -717 -5.19 2,620 30.15 0.1885
2022-08-01 2022-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 13,805 -1,170 -7.81 2,013 -17.67 0.1278
2022-05-10 2022-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 14,975 -1,471 -8.94 2,445 -12.33 0.1027
2022-02-08 2021-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 16,446 -2,826 -14.66 2,789 -23.36 0.0912
2021-11-12 2021-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 19,272 -789 -3.93 3,639 7.03 0.1226
2021-08-12 2021-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 20,061 -552 -2.68 3,400 16.84 0.1142
2021-05-14 2021-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 20,613 -3,060 -12.93 2,910 -5.43 0.1119
2021-02-09 2020-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 23,673 2,117 9.82 3,077 -1.98 0.1345
2020-11-13 2020-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 21,556 -3,501 -13.97 3,139 -15.41 0.1615
2020-08-03 2020-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 25,057 4,111 19.63 3,711 62.76 0.2065
2020-05-15 2020-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 20,946 -7,643 -26.73 2,280 -30.76 0.1712
2020-02-18 2019-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 28,589 2,996 11.71 3,293 60.01 0.1434
2019-11-12 2019-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 25,593 2,236 9.57 2,058 21.42 0.1041
2019-08-13 2019-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 23,357 -2,992 -11.36 1,695 -31.15 0.0804
2019-05-15 2019-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 26,349 1,655 6.70 2,462 36.78 0.1184
2019-02-14 2018-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 24,694 -5,926 -19.35 1,800 -32.84 0.1113
2018-11-13 2018-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 30,620 4,671 18.00 2,680 4.85 0.1017
2018-08-13 2018-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 25,949 -1,152 -4.25 2,556 -20.82 0.1021
2018-05-14 2018-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 27,101 -2,846 -9.50 3,228 -15.16 0.1285
2018-02-14 2017-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 29,947 -1,502 -4.78 3,805 2.98 0.1467
2017-11-13 2017-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 31,449 537 1.74 3,695 49.84 0.1538
2017-08-11 2017-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 30,912 1,774 6.09 2,466 65.17 0.1117
2017-04-25 2017-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 29,138 -2,342 -7.44 1,493 26.63 0.0667
2017-02-13 2016-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 31,480 -4,984 -13.67 1,179 -52.31 0.0543
2016-11-10 2016-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 36,464 -3,640 -9.08 2,472 11.10 0.1176
2016-08-12 2016-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 40,104 -1,708 -4.08 2,225 -15.24 0.1083
2016-05-06 2016-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 41,812 -9,922 -19.18 2,625 -46.10 0.1360
2016-02-05 2015-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 51,734 -105 -0.20 4,870 16.90 0.2311
2015-11-06 2015-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 51,839 -2,922 -5.34 4,166 -36.53 0.2374
2015-08-11 2015-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 54,761 -102 -0.19 6,564 14.57 0.2718
2015-05-08 2015-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 54,863 54,863 0.00 5,729 0.2228
2015-01-30 2014-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -41,636 -100.00 0 -100.00
2014-11-06 2014-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 41,636 3,676 9.68 3,252 35.61 0.1523
2014-08-08 2014-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 37,960 -6,650 -14.91 2,398 -19.93 0.1052
2014-05-07 2014-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 44,610 9,331 26.45 2,995 32.00 0.1361
2014-02-04 2013-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 35,279 7,727 28.05 2,269 28.63 0.1017
2013-11-07 2013-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 27,552 27,552 1,764 0.0936
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.